Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The revenues this quarter are in line with the outlook we envisaged for the year
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
Over 8.8?million Indians aged 60 and above currently live with dementia,
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Subscribe To Our Newsletter & Stay Updated